142 related articles for article (PubMed ID: 38192144)
1. Triple Action of Lignosulfonic Acid Sodium: Anti-protease, Antioxidant, and Anti-inflammatory Effects of a Polymeric Heparin Mimetic.
Al-Horani RA; Aliter KF
Med Chem; 2024 Jan; ():. PubMed ID: 38192144
[TBL] [Abstract][Full Text] [Related]
2. Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa.
Kar S; Bankston P; Afosah DK; Al-Horani RA
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577586
[TBL] [Abstract][Full Text] [Related]
3. Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase.
Al-Horani RA; Aliter KF; Kar S; Mottamal M
ACS Omega; 2021 May; 6(19):12699-12710. PubMed ID: 34056422
[TBL] [Abstract][Full Text] [Related]
4. Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.
Voynow JA; Zheng S; Kummarapurugu AB
Front Pharmacol; 2020; 11():1011. PubMed ID: 32733248
[TBL] [Abstract][Full Text] [Related]
5. Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation.
Saluja B; Thakkar JN; Li H; Desai UR; Sakagami M
Pulm Pharmacol Ther; 2013 Apr; 26(2):296-304. PubMed ID: 23280431
[TBL] [Abstract][Full Text] [Related]
6. Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway.
Ghonim MA; Wang J; Ibba SV; Luu HH; Pyakurel K; Benslimane I; Mousa S; Boulares AH
J Transl Med; 2018 Sep; 16(1):243. PubMed ID: 30172259
[TBL] [Abstract][Full Text] [Related]
7. Homogeneous, Synthetic, Non-Saccharide Glycosaminoglycan Mimetics as Potent Inhibitors of Human Cathepsin G.
Afosah DK; Fayyad RM; Puliafico VR; Merrell S; Langmia EK; Diagne SR; Al-Horani RA; Desai UR
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238630
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the anticoagulant activity of cyclic sulfated glycosaminoglycan mimetics.
Chiles R; Afosah DK; Al-Horani RA
Carbohydr Res; 2023 Jul; 529():108831. PubMed ID: 37209666
[TBL] [Abstract][Full Text] [Related]
9. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
10. Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.
Stone AL; Melton DJ; Lewis MS
Glycoconj J; 1998 Jul; 15(7):697-712. PubMed ID: 9881776
[TBL] [Abstract][Full Text] [Related]
11. Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases.
Henry BL; Thakkar JN; Liang A; Desai UR
Biochem Biophys Res Commun; 2012 Jan; 417(1):382-6. PubMed ID: 22155248
[TBL] [Abstract][Full Text] [Related]
12. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
13. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
[TBL] [Abstract][Full Text] [Related]
14. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
Hirsh J
Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
[TBL] [Abstract][Full Text] [Related]
15. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
16. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
17. Size-fractionated heparins have differential effects on human neutrophil function in vitro.
Lever R; Lo WT; Faraidoun M; Amin V; Brown RA; Gallagher J; Page CP
Br J Pharmacol; 2007 Jul; 151(6):837-43. PubMed ID: 17533420
[TBL] [Abstract][Full Text] [Related]
18. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G.
Evangelista V; Piccardoni P; Maugeri N; De Gaetano G; Cerletti C
Eur J Pharmacol; 1992 Jun; 216(3):401-5. PubMed ID: 1425930
[TBL] [Abstract][Full Text] [Related]
19. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes.
Hochart H; Jenkins PV; Smith OP; White B
Br J Haematol; 2006 Apr; 133(1):62-7. PubMed ID: 16512830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
